CASM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. CAS Medical Systems's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 was $0.789. CAS Medical Systems's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-05-14), CAS Medical Systems's share price is $2.45. CAS Medical Systems's Median PS Value is $0.00. Therefore, CAS Medical Systems's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for CAS Medical Systems's Median PS Value or its related term are showing as below:
The historical data trend for CAS Medical Systems's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS Medical Systems Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
CAS Medical Systems Quarterly Data | ||||||||||||||||||||
Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Instruments & Supplies subindustry, CAS Medical Systems's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, CAS Medical Systems's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where CAS Medical Systems's Price-to-Median-PS-Value falls into.
CAS Medical Systems's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0.789 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
CAS Medical Systems's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.789.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS Medical Systems (NAS:CASM) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
CAS Medical Systems's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 2.45 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CAS Medical Systems's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan Milinazzo | director | C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078 |
Thomas M Patton | director, officer: President and CEO | C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724 |
Kenneth R Weisshaar | director | 875 PARK AVE APT 2D, NEW YORK NY 10021 |
James E Thomas | director, 10 percent owner | WOODS END ROAD, NEW CANAAN CT 06840 |
Thomas, Mcnerney & Partners Ii L.p. | 10 percent owner | 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402 |
Tmp Associates Ii Lp | 10 percent owner | 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Tmp Nominee Ii, Llc | 10 percent owner | 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Thomas, Mcnerney & Partners Ii, Llc | 10 percent owner | 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402 |
Acuta Capital Fund, Lp | 10 percent owner | 1301 SHOREWAY ROAD, SUITE 350, BELMONT CA 94002 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Management Company, L.p. (series C) | 10 percent owner, other: Possible Member of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
Deerfield Mgmt L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Special Situations Fund, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Special Situations International Master Fund, L.p. | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Lawrence Burstein | director | C/O UNITY VENTURE CAPITAL ASSOCIATES LTD, 245 FIFTH AVENUE, SUITE 1500, NEW YORK NY 10016 |
From GuruFocus
By Marketwired Marketwired • 01-04-2019
By Marketwired Marketwired • 05-03-2018
By PRNewswire PRNewswire • 02-15-2019
By gurufocus • 05-07-2009
By gurufocus 10qk • 11-10-2010
By PRNewswire PRNewswire • 03-05-2019
By Marketwired Marketwired • 03-28-2019
By gurufocus 10qk • 05-05-2010
By Marketwired Marketwired • 11-13-2018
By PRNewswire PRNewswire • 03-19-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.